NATCO PHARMA USA
GenericsNATCO PHARMA USA is a generic drug manufacturer focused on Cardiovascular, Oncology, Metabolic.
NATCO PHARMA USA's Key Drugs
NATCO PHARMA USA's core commercial portfolio centers on OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, spanning Cardiovascular and Oncology — its most strategically important drugs approved in the last 15 years.
NATCO PHARMA USA's Recent FDA Approvals
New NDA/BLA approvals for NATCO PHARMA USA over the last two years — novel drugs only, excluding generics and label supplements.
NATCO PHARMA USA's Therapeutic Areas
NATCO PHARMA USA's approved drugs and pipeline span 4 therapeutic areas, led by Cardiovascular and Oncology, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
NATCO PHARMA USA's Top Competitors
NATCO PHARMA USA's closest competitors by therapeutic-area and drug-target overlap include Merck, Baxter, and AZURITY. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
NATCO PHARMA USA Pipeline Snapshot
Active clinical trials for NATCO PHARMA USA across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 1987-10-19
- Latest
- 2025-08-21
- Applications
- 19